Portside Wealth Group
TGTX icon

Portside Wealth Group’s TG Therapeutics TGTX Stock Holding History

Portside Wealth Group’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$974K Buy
17,470
+1,012
+6% +$54.8K 0.11% 190
2026
Q2 		$904K Buy
16,458
+2,630
+19% +$108K 0.11% 209
2026
Q1 		$459K Buy
13,828
+1,777
+15% +$53K 0.06% 275
2025
Q4 		$359K Buy
+12,051
New +$394K 0.05% 325

Other funds holding TGTX

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 20.64% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Portside Wealth Group's TGTX Position: Q3 2026 in Review

Portside Wealth Group increased its TG Therapeutics (TGTX) stake by 6.1% in Q3 2026, buying an estimated $54.8K and bringing the position to 17,470 shares worth $974K. The position accounts for 0.11% of the portfolio, ranked #190.

Portside Wealth Group first reported a position in TGTX in Q4 2025 and has held it in 4 quarters since. 305 funds tracked by Wall St. Rank hold TGTX as of Q3 2026.

  • Portside Wealth Group held 17,470 shares of TG Therapeutics worth $974K as of Q3 2026.
  • Portside Wealth Group bought 1,012 TG Therapeutics shares in Q3 2026, an estimated $54.8K.
  • TG Therapeutics made up 0.11% of Portside Wealth Group's portfolio in Q3 2026, its #190 holding.
  • Portside Wealth Group first reported a position in TG Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • 305 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2026.

Based on Portside Wealth Group's 13F filing for Q3 2026, filed 20 Oct 2026.